Search Result
Results for "
5-Aminosalicylic Acid
" in MedChemExpress (MCE) Product Catalog:
9
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15027
-
-
-
- HY-15027S
-
-
-
- HY-15027S1
-
-
-
- HY-143704S
-
|
Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride
|
PPAR
NF-κB
PAK
|
Metabolic Disease
|
|
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-66008
-
|
N-Acetyl-5-Aminosalicylic Acid; N-Acetyl-ASA
|
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
|
N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-15027R
-
|
Mesalamine (Standard); 5-ASA (Standard); Mesalazine (Standard)
|
Reference Standards
PPAR
PAK
NF-κB
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
-
-
- HY-15027S4
-
|
5-ASA-d7; Mesalamie-d7; Mesalazie-d7
|
Isotope-Labeled Compounds
PPAR
PAK
Endogenous Metabolite
NF-κB
|
Inflammation/Immunology
Cancer
|
|
5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .
|
-
-
- HY-15027S3
-
|
Mesalamine-d3 disodium; 5-ASA-d3 disodium; Mesalazine-d3 disodium
|
PPAR
NF-κB
Endogenous Metabolite
PAK
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
|
5-Aminosalicylic acid-d3 disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
-
-
- HY-15027S2
-
|
Mesalamine-13C6; 5-ASA-13C6; Mesalazine-13C6
|
PPAR
PAK
NF-κB
Endogenous Metabolite
|
Inflammation/Immunology
|
|
5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-66008R
-
|
N-Acetyl-5-Aminosalicylic Acid (Standard); N-Acetyl-ASA (Standard)
|
Drug Metabolite
Reference Standards
|
Inflammation/Immunology
Cancer
|
|
N-Acetyl mesalazine (Standard) (N-Acetyl-5-aminosalicylic acid (Standard)) is the analytical standard of N-Acetyl mesalazine (HY-66008). This product is intended for research and analytical applications. N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-66008S
-
|
N-Acetyl-5-Aminosalicylic Acid-d3; N-Acetyl-ASA-d3
|
Isotope-Labeled Compounds
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
|
N-Acetyl mesalazine-d3 (N-Acetyl-5-aminosalicylic acid-d3) is the deuterium labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-66008S1
-
|
N-Acetyl-5-Aminosalicylic Acid-d3-1; N-Acetyl-ASA-d3-1
|
Isotope-Labeled Compounds
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
|
N-Acetyl mesalazine-d3-1 (N-Acetyl-5-aminosalicylic acid-d3-1) is deuterium labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-66008S2
-
|
N-Acetyl-5-Aminosalicylic Acid-13C6; N-Acetyl-ASA-13C6
|
Isotope-Labeled Compounds
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
|
N-Acetyl mesalazine- 13C6 (N-Acetyl-5-aminosalicylic acid- 13C6) is a deuterated labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-W206016
-
|
|
Drug Intermediate
|
Inflammation/Immunology
Cancer
|
|
3-Aminosalicylic acid is the impurity found during the 5-Aminosalicylic acid (HY-15027) production. 5-Aminosalicylic acid is the agonist for PPARγ and the inhibitor for p21-activated kinase 1 (PAK1) and NF-κB .
Crohn's disease, ulcerative proctitis
|
-
-
- HY-101744
-
|
|
Autophagy
|
Inflammation/Immunology
|
|
Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.
|
-
-
- HY-W094747A
-
|
|
Drug Intermediate
|
Inflammation/Immunology
|
|
Benzalazine is a 5-azo derivative of 5-Aminosalicylic Acid (HY-15027) that can be used for the research of ulcerative colitis and Crohn's disease of the large intestine. The benzalazine metabolite 5-ASA and the 5-ASA metabolite acetyl-5-aminosalicylic acid are excreted mainly with the faeces .
|
-
-
- HY-131265
-
|
|
PPAR
PAK
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Mesalamine impurity P is an impurity of Mesalamine (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
-
- HY-P4146A
-
|
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-P4146
-
|
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4146A
-
|
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146
-
|
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-15027S
-
|
|
|
5-Aminosalicylic Acid-d3 (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
|
-
-
- HY-15027S1
-
|
|
|
5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-143704S
-
|
|
|
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-66008S
-
|
|
|
N-Acetyl mesalazine-d3 (N-Acetyl-5-aminosalicylic acid-d3) is the deuterium labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-15027S4
-
|
|
|
5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .
|
-
-
- HY-15027S3
-
|
|
|
5-Aminosalicylic acid-d3 disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
-
-
- HY-15027S2
-
|
|
|
5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-66008S1
-
|
|
|
N-Acetyl mesalazine-d3-1 (N-Acetyl-5-aminosalicylic acid-d3-1) is deuterium labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
-
- HY-66008S2
-
|
|
|
N-Acetyl mesalazine- 13C6 (N-Acetyl-5-aminosalicylic acid- 13C6) is a deuterated labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
